ArticleMolecules (Basel, Switzerland)2013
Isoliquiritigen enhances the antitumour activity and decreases the genotoxic effect of cyclophosphamide.
Article in Molecules (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Anticancer efficacy of nerolidol, cyclophosphamide, and their combination against breast cancer cell line MCF-7.Medical oncology (Northwood, London, England) · 2025Article
- Vaginal host immune-microbiome-metabolite interactions associated with spontaneous preterm birth in a predominantly white cohort.NPJ biofilms and microbiomes · 2025Article
- Physio-biochemical and metabolomic responses of the woody plant Dalbergia odorifera to salinity and waterlogging.BMC plant biology · 2024Article
- Licorice (OncoTargets and therapy · 2022Review
- Review
- Perspectives on the Role of Isoliquiritigenin in Cancer.Cancers · 2021Review
- Isoliquiritigenin Pretreatment Induces Endoplasmic Reticulum Stress-Mediated Hormesis and Attenuates Cisplatin-Induced Oxidative Stress and Damage in LLC-PK1 Cells.Molecules (Basel, Switzerland) · 2020Article
- Isobavachalcone Induces ROS-Mediated ApoptosisOxidative medicine and cellular longevity · 2018Article
- Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism.Oncology letters · 2017Article
- Effects of isoliquiritigenin on ovarian antral follicle growth and steroidogenesis.Reproductive toxicology (Elmsford, N.Y.) · 2016Article
- Jolkinolide B induces apoptosis and inhibits tumor growth in mouse melanoma B16F10 cells by altering glycolysis.Scientific reports · 2016Article
- Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the antitumour activities and genotoxic effects of isoliquiritigenin (ISL) combined with cyclophosphamide (CP) in vitro and in vivo. U14 cells were treated with either of ISL (5-25 μg/mL) or CP (0.25-1.25 mg/mL) alone or with combination of ISL (5-25 μg/mL) and CP (1.0 mg/mL) for 48 h. The proliferation inhibitory effect in vitro was evaluated by MTT and colony formation assays. KM mice bearing U14 mouse cervical cancer cells were used to estimate the antitumour activity in vivo. The genotoxic activity in bone marrow polychromatic erythrocytes was assayed by frequency of micronuclei. The DNA damage in peripheral white blood cells was assayed by single cell gel electrophoresis. The results showed that ISL enhanced antitumour activity of CP in vitro and in vivo, and decreased the micronucleus formation in polychromatic erythrocytes and DNA strand breaks in white blood cells in a dose-dependent way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.